



9th Global

DDF Summit

Drug Delivery & Formulation

12 – 14 March 2018 | Berlin

**THE FUTURE OF
PHARMACEUTICAL
DEVELOPMENT**

SUMMIT BROCHURE

“Very inspiring and well given talks and numerous opportunities to share experiences across the industry”

Cornelius Pompe, Amgen

Where innovation meets industrial application

The DDF Summit brings industry and academia's brightest minds together to discuss shared drug delivery challenges. It's all about providing a quality, useful experience for pharmaceutical development leaders.

The streamed agenda and intermittent keynotes combine to give you laser focused, highly scientific sessions alongside insightful overviews of exciting pharmaceutical development trends.

Engaging speakers with decades of experience will deliver educational and enlightening presentations. Topics are chosen to stimulate fruitful discussions on issues owned by the whole drug delivery and formulation field.

Industry scientists, academics and technology providers will all be present to share their latest

work, ideas and opinions. The number, balance and level of attendees in the networking hall creates the perfect environment for meaningful and productive conversations.

It's the mix of a shared academic mindset within a commercial culture that makes the DDF Summit such a valuable and rewarding networking opportunity.

If this is something you'd like to be a part of then I look forward to welcoming to Berlin in March.



Gurtej Johal

Head of Content
MA Exhibitions

*"Very interesting summit.
Speakers were very
engaging and it's motivating
to see the innovation that's
occurring in the pharma and
biopharma industries."*

Anita Lombard, Stryker

*"A good combination of
scientific presentation
and more long-term
visions of pharma
management"*

Helen Sjögren, Ferring
Pharmaceuticals

Top 10 reasons to attend

- 1 Hear from over 60 expert speakers from across industry and academia
- 2 Grow your network with 400+ senior delivery and formulation professionals
- 3 Meet 30+ innovative delivery and formulation technology and service providers
- 4 Delve deep into the science with focused streams on Small Molecules, Biologics and Technology
- 5 Get the latest on delivery devices in the brand new dedicated Device Development stream
- 6 Understand and explore current and future industry trends
- 7 Present your own work with the Poster Competition – new for 2018
- 8 Take part in pre-arranged 1-2-1 meetings with companies most likely to solve your challenges
- 9 Network online before, during and the after the summit using the official event app
- 10 Gain access to the presentation slides after the summit

Agenda

Day 1

07:30–08:20

Registration

08:20–08:30

Chair's Opening Remarks

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

08:30–09:10 Keynote

Transforming the Small Molecule to Medicine Product Design Process?

Brian Henry, Vice President, Drug Product Design, Pfizer

Stream Chairs:

Small Molecules

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

Biologics

Patrick Garidel, Boehringer Ingelheim

Technology & Innovation

TBC

Device Development

TBC

09:15–09:50

Small Molecules

Solvent-Induced Phase Separation in Amorphous Solid Dispersions

Gabriele Sadowski, Faculty Head, Univ. of Dortmund

Biologics

Fixed Dose mAb Combinations: A recent Case Study Highlighting CMC Development Challenges and Strategies

Tarik Khan, Group Leader / Scientist, Roche

Technology & Innovation

Control Strategies in Continuous Manufacturing at Novartis – Case Studies

Markus Krumme, Head of Continuous Manufacturing, Novartis

Device Development

Global Regulatory Strategies for Combination Product Registration and Change Management

Martin McLoughlin, Head of Device Development, Bristol-Myers Squibb

09:50–10:25

Small Molecules

Combination Treatment of Multidrug Resistant Tumors with Stimuli-Sensitive Nanocarriers Co-Loaded with siRNA and Drugs

Speaker TBC

Biologics

Biopharmaceutics as Catalyst for Quality by Design

Jérôme Mantanus, Head of Formulation and Process Characterization, UCB Pharma

Technology & Innovation

Manufacturing the Future: a Strategic Approach to Product and Process development by Continuous Manufacturing

Giustino Di Pretoro, Associate Director, Johnson & Johnson

Device Development

Left to Our Own Devices: Design Control and Risk Management Strategies for Combination Products

Richard Wedge, Director Design Control Implementation, Pfizer

Agenda *continued*

10:25–11:25

iSolve & Break

11:30–12:05

Small Molecules

Microenvironmental pH Modulation – An Effective Tool in Enhancing Dissolution and Oral Absorption of Solid Dosage Forms

Helen Hao Hou, Scientist, Genentech

Biologics

A Thermodynamic Approach to Explore Excipient Mixtures and Novel Excipients in High Concentration Protein Formulations

Dr. Christoph Brandenbusch, Group Leader, TU Dortmund

Technology & Innovation

Facilitating Meaningful Differentiation of Products by Establishing a Culture of Innovation

Dr. Stefan Holzner, Senior Director Device Development, Shire

Device Development

The Continually Evolving Biologics Field and the Inherent Effect on Drug Delivery Device Design - a Strategic Approach to Designing Platform Devices for Operational Efficiency

Brian Holt, Principal Engineer, Device & Final Drug Product Technologies, Amgen

12:10–12:45 Solution Spotlights

Small Molecules

Solution Spotlight with REVOX sterilization solutions

Biologics

Solution Spotlight with Pfanstiehl

Technology & Innovation

Solution Spotlight with Losan Pharma

Device Development

Solution Spotlight

12:45–13:45

Networking Lunch

13:45–14:20

Small Molecules

Differentiating Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane

Bernard Van Eerdenbrugh, Fellow, Chemical and Pharmaceutical Profiling, Novartis Pharma AG

Biologics

Protein Aggregation in Multidose Parenteral Formulations: Challenges During Formulation Development

Dr. Kathrin Spielberger, Senior Scientist Product & Process Development, Sanofi

Technology & Innovation

Combining the Best of Two Worlds: Using High Throughput Physico-Chemical Testing & Biorelevance Assays in Biotherapeutics Development

Sabine Eichling, Senior Scientist II, NBE High-Throughput and Advanced Formulation Sciences, Abbvie

Device Development

Who Moved my Device? – a Talk On Working within the Changing Regulatory Landscape around Combination and Medical Devices

Björg Kaae Hunter, Device Engineering Manager, GlaxoSmithKline

14:25–15:00 Solution Spotlights

Small Molecules

Solution Spotlight with Grace

Biologics

Solution Spotlight with Unchained Labs

Technology & Innovation

Solution Spotlight with LTS

Device Development

Solution Spotlight

Agenda *continued*

15:05-15:40 Solution Spotlights

Small Molecules

The Unmet Need of Biodegradable Parenteral Controlled Release DDS: Concept, Performance and Perspectives

Karsten Mäder, Professor of Pharmaceutics, Martin-Luther-University Halle Wittenberg

Biologics

Biopharmaceutics Risk Assessment During Formulation and Clinical Development

Filippos Kesisoglou, Senior Principal Scientist, Biopharmaceutics, Pharmaceutical Sciences and Clinical Supply, MSD

Technology & Innovation

Novel Developments in the Formulation of Amorphous Solid Dispersions

Prof. Thomas Rades, Chair Pharmaceutical Sciences Univ of Copenhagen

Device Development

Risk Management and Formative Human Factor Studies

Muriel Didier, Human Factors Team Head, Novartis

15:40-16:40

iSolve & Break

16:40-17:15

Small Molecules

Absorption Modelling in Regulatory Context – from IVIVC to PBPK

Bertil Abrahamsson, Senior Principal Scientist, AstraZeneca

Biologics

Protein-Based Nanoparticles for Drug Delivery Purposes

Juan M. Irache, Professor, University of Navarra

Technology & Innovation

Manufacturing Innovation – Bringing New Technologies from the Lab to the Shop Floor

Robert Meyer, Principal Scientist, Innovation and New Technology Development, MSD

Device Development

Bridging between Device Types during Clinical Development

Chris Muenzer, Senior Device Engineer, Roche Switzerland

17:15-17:50

Keynote: Technical Integration of Device Systems and Associated Business Process to Accelerate Innovation

Justin M Wright, PhD, Vice President, Drug Delivery Innovation, Drug Delivery and Device R&D, Eli Lilly and Company

17:50-18:00

Chair's Closing Remarks

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

Agenda *continued*

Day 2

08:00–08:35

Registration

08:35–08:40

Chair's Opening Remarks

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

08:40–09:15 Keynote

In What Direction is the Drug Delivery Technology Space Moving?

Anand Subromony, Vice President New Product Technologies, MedImmune

09:15–09:50

In What Direction is the Drug Delivery Technology Space Moving?

Anand Subromony, Vice President New Product Technologies, MedImmune

Small Molecules

Leveraging Prediction Tools to Accelerate Product Development

Jatin Patel, Head - Oral Product Design & Development, Bristol-Myers Squibb

Biologics

Foundational Research on Subcutaneous Injection Physiology to Improve Biologics Delivery Systems and Patient Experience

Justin M Wright, PhD Vice President, Drug Delivery Innovation Drug Delivery and Device R&D, Eli Lilly and Company

Technology & Innovation

Jet Milling Industrialization of Sticky Active Pharmaceutical Ingredient using QbD Approach

Mostafa Nakach, Head of Pharmaceutical engineering, Sanofi

Device Development

Strategies for Developing Value-Added Complex Injectable Generics

Surendera Tyagi, Head Innovation & Development Center, US Fresenius Kabi USA

09:50–10:50

iSolve & Break

10:50–11:25

Small Molecules

Quantitative Biopharmaceutics: Use of Modeling and Simulation to Inform API and Formulation Decisions

Filippos Kesisoglou, Senior Principal Scientist, Biopharmaceutics, Pharmaceutical Sciences and Clinical Supply, MSD

Biologics

Formulation Design of Smaller Proteins and Insulin for Multiple Injection Dosing and/or Infusion

Svend Ludvigsen, Senior Scientific Director Novo Nordisk A/S

Technology & Innovation

Integration of Solid Form Selection and Biopharmaceutical Risk Assessment into Drug Product Design in the Early Phase Development

Professor Duncan Craig, Director Pharmaceutics, UCL School of Pharmacy

Device Development

Trends and Challenges in Inhaled Drug Delivery Transforming Respiratory Drug Portfolios

Gunilla Petersson, Science & Innovation Director, AstraZeneca Sweden

Agenda *continued*

11:30–12:05 Solution Spotlights

Small Molecules	Solution spotlight with Grace Hovione
Biologics	Solution spotlight with Alumedix
Technology & Innovation	Solution spotlight with DFE pharma
Device Development	Solution spotlight

12:10–12:45

Small Molecules	Oral Delivery of Hydrophobic Drugs using Mixed Micelles Rene Van Nostrum , Associate Professor Utrecht University Netherlands
Biologics	Oral Peptide Technologies Progressing in the Clinic: Addressing Challenges to Bring New Products to the Market Joel Richard , SVP Peptides Ipsen
Technology & Innovation	The Next Wave of Innovation in the Parenteral Space - A Stimulus Talk with Voting on Questions Bernd Riebesehl , Distinguished Fellow Novartis Pharma AG
Device Development	Tissue Specific Delivery Using Caveolae Technology Improves Drug Efficacy Ruchi Gupta , Scientis I, MedImmune

12:45–13:45

Networking Lunch

13:45–14:20

Small Molecules	Early “Developability” Assessment, Key to Success in Development Phases Philippe Lienard , CMC Discovery Coordinator Sanofi
Biologics	Mucoadhesive Polymers: Product Developments and Future Trends Andreas Bernkop-Schnürch , Prof. Institute of Pharmacy, Universität Innsbruck
Technology & Innovation	Microneedles: From Basic Research to a Drug Product Yash Kapoor , Associate Principal Scientist, MSD
Device Development	Implementing Human Factors Engineering and User-Centered Design: Practical Guidance for Combination Products Speaker TBC

14:25–15:00 Solution Spotlights

Small Molecules	Solution Spotlight with Dow
Biologics	Solution Spotlight
Technology & Innovation	Solution Spotlight with Capsugel Now a Lonza Company
Device Development	Solution Spotlight

15:00–15:50

Break

Agenda *continued*

15:50–16:25

Small Molecules

User Friendly Medicines

J. P. Todd, Professor of Pharmaceutics, University of Strathclyde

Biologics

Thermal Stabilization of Freezing Sensitive Adjuvanted Vaccine Formulations Through Spray Drying

Speaker TBC

Technology & Innovation

Novel Approaches for Efficient Topical Delivery of Small - and Biomacromolecules

Sarah Hedtrich, Assistant Professor for Pharmacology, Freie Universität Berlin

Device Development

Reviewing the Newly Introduced Rule 21 on the Classification of Substance-Based Devices and How This May Impact Borderline Product Cases

Speaker TBC

16:30–17:05 Solution Spotlights

Small Molecules

Solution Spotlight with Patheon

Biologics

Solution Spotlight

Technology & Innovation

Solution Spotlight with ADM SIO

Device Development

Solution Spotlight

17:10–17:45 Keynote

Panel Discussion: How Big Data and Artificial Intelligence Can Revolutionize Pharmaceutical R&D

Panel Chair:

Olaf Queckenberg

Panellists:

Brian Henry, Vice President, Drug Product Design **Pfizer**

Anand Subramony, VP, Drug Delivery & Device Development, **MedImmune**

Justin M Wright, PhD Vice President, Drug Delivery Innovation, Drug Delivery and Device R&D, **Eli Lilly and Company**

17:45–17:55

Chair's Closing Remarks:

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, **Bayer AG Germany**

Agenda *continued*

Day 3

08:00–08:20

Registration

08:20–08:30

Chair's Opening Remarks

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

08:30 09:05

Smart Drug Delivery systems: Going Inside Cells and to Individual Organelles

Vladimir Torchilin, University Distinguished Professor, Director, Center for Pharmaceutical Biotechnology and Nanomedicine Northeastern University

09:10–09:45

Small Molecules

Challenges and Opportunities of Developing Pediatric Drug Formulations

Speaker TBC

Biologics

New Approaches to Advance Therapeutic Drug Delivery across the Blood-Brain Barrier to Brain and Brain Tumours

Stephen Buckley, Head of Department Absorption and Biological MS Novo Nordisk

Technology & Innovation

Recent Advances in the Development of Ocular Drug Delivery Systems

Gregoire Schwach, Head of Drug Delivery, Pharmaceutical Development and Supplies Biologics EU F. Hoffmann-La Roche

09:50–10:25 Solution Spotlights

Small Molecules

Solution Spotlight with Quotient Clinical

Biologics

Solution Spotlight with TBC

Technology & Innovation

Solution Spotlight with Merck KGaA

10:25–10:45

Break

10:45–11:15

Small Molecules

Ensuring Age-Appropriate Medicines for Children

Hannah Batchelor, Senior Lecturer in Pharmaceutics, Formulation and Drug Delivery Director of Research, School of Pharmacy, University of Birmingham

Biologics

Knowledge-Based Selection Strategies Using the QbD Approach to Ensure Syringe Selection Decisions Meet Technical and Business Requirements

Kenneth Graham, Senior Fellow Scientist, Associate Director, Regeneron

Technology & Innovation

Innovative Ocular Drug Delivery Systems

Dr Thakur Raghu Raj Singh, Senior Lecturer in Pharmaceutics Queens University Belfast

Agenda *continued*

11:15-11:50

Small Molecules

Nanoparticle Formulation Development: A Closer look at Pharmaceutical Fabrication Methods

Biologics

General overview on technologies that enable controlled targeted drug delivery and drug release at the site of action

Speaker TBC

Technology & Innovation

Introduction on "Next Generation Biologics"

Carsten Olbrich, Product Quality Steward Eylea and Anetumab Ravstantine, Bayer

11:55-12:30 Solution Spotlights

Small Molecules

Solution Spotlight with Roquette

Biologics

Solution Spotlight

Technology & Innovation

Solution Spotlight with Foster Delivery Science

12:30-13:40

Networking Lunch

13:40-14:15

Small Molecules

Advances in Supersaturating Drug Delivery Systems

Christophe Tistaert, Senior Scientist, Janssen Belgium

Biologics

Bioinspired Drug Delivery Systems

Lorenz Meinel, Director and Chair University of Würzburg

Technology & Innovation

Cryopreservation of Ex Vivo Cell and Gene Therapies

Richard Zajicek, Head of Cell and Gene Therapy Formulation GSK

14:15-14:50 Case Study

Small Molecules

Challenges and Opportunities of Development of Salts of Weak Bases

Speaker TBC

Biologics

Scalable Manufacturing of the Next Generation of Liposomal Vaccines.

Yvonne Perrie, Prof in Drug Delivery University of Strathclyde

Technology & Innovation

Nucleic Acid Based Therapeutics for Cancer: Targeted Delivery Systems and in Vivo Bioimaging

Manfred Ogris, Professor, Division of Clinical Pharmacy and Diagnostics Vienna University

14:55-15:35

Keynote

Speaker TBC

15:35-15:45

Chair's Closing Remarks:

Olaf Queckenberg, Head of Global Chemical & Pharmaceutical Development, Bayer AG Germany

Speakers



Ahmed Basheer
Principal Scientist **Novartis**



Anand Subromony
Vice President Drug Delivery
& Device Development
MedImmune



Andreas Bernkop-Schnürch
Professor
University of Innsbruck



Aniket Badkar
Associate Director Biologics
Product Development **Allergan**



Bernard van Eerdenbrugh
Pre-clinical Formulation Expert,
Chem. & Pharmaceut. Profiling
Technical R&D **Novartis**



Bernd Riebesehl
Distinguished Fellow
Novartis Pharma AG



Bjørg Hunter
Device Engineering Manager
GlaxoSmithKline



Carsten Olbrich
Product Quality Steward Eylea
and Anetumab Ravstentine
Bayer



Brian Henry
Vice President Drug Product
Design **Pfizer**



Brian Holt
Principal Engineer Device
& Final Drug Product
Technologies **Amgen**



Richard Wedge
Compliance Lead **Pfizer**



Christoph Brandenbusch
Associate Professor
University of Dortmund



Clive Wilson
J.P. Professor of Pharmaceutics
University of Strathclyde



Daniel Schweizer
DP Project Lead TD NBE's
Novartis



Professor Duncan Craig
Director, Chair in Drug Delivery
UCL School of Pharmacy



Filippou Kesisoglou
Senior Principal Scientist,
Biopharmaceutics and
Pharmaceutical Sciences **MSD**



Prof. Gabriele Sadowski
Prof. Thermodynamics,
Department of Biochemical and
Chemical Eng. **TU Dortmund**



Giustino Di Pretoro
Associate Director, Continuous
Manufacturing **Janssen**



Gregoire Schwach
Head of Drug Delivery, PTD
Biologics Europe **Roche**



Hannah Batchelor
Senior Lecturer in
Pharmaceutics, Formulation
and Drug Delivery
University of Birmingham



Helen Hao Hou
Scientist, Small Molecule
Pharmaceutical Sciences
Genentech



Jatin Patel
Head – Oral Product Design &
Development
Bristol-Myers Squibb



Jerome Mantanus
Head of Formulation and
Process Characterisation
UCB



Joel Richard
Senior Vice President, Peptides
Ipsen



Juan Irache
Professor of Pharmaceutical
Technology
University of Navarra



Jukka Rantanen
Professor Pharmaceutical
Technology
University of Copenhagen



Justin Wright
Vice President Delivery and
Device Innovation
Eli Lilly and Company



Prof. Dr. Karsten Mäder
Head of Pharmaceutical
Technology **Martin Luther**
University Halle-Wittenberg

Speakers *continued*



Kathrin Spielberger
Lab Head Formulation
Development **Sanofi**



Olaf Queckenberg
Head of Chemical &
Pharmaceutical Development
Bayer AG



Svend Ludvigsen
Senior Scientific Director
Novo Nordisk



Kenneth Graham
Senior Fellow Scientist,
Associate Director **Regeneron**



Philippe Lienard
CMC Discovery Coordinator
Sanofi



Tarik Khan
Group Leader, Late-Stage
Pharmaceutical and Processing
Development **Roche**



Lorenz Meinel
Chair for Drug Formulation and
Delivery **Wurzburg University**



Rene Van Nostrum
Associate Professor
Utrecht University



Thakur Raj Singh
Senior Lecturer in
Pharmaceutics
Queen's University Belfast



Manfred Ogris
Professor, Head of Laboratory
for Molecular Cancer
Therapeutics
Vienna University



Robert Meyer
Head of Innovation Technology
Group, Pharmaceutical
Commercialization **MSD**



Thomas Rades
Chair Pharmaceutical Sciences
University of Copenhagen



Markus Krummer
Head of Continuous
Manufacturing **Novartis**



Prof. Dr. Sarah Hedtrich
Professor
Freie Universitat Berlin



Vladimir P. Torchilin
Distinguished Professor
Northeastern University



Martin McLoughlin
Head of Device Development
Bristol-Myers Squibb



Stephen Buckley
Head of Department,
Absorption and Biological MS
Novo Nordisk



Yash Kapoor
Associate Principal Scientist
MSD



Muriel Didier
Human Factors Team Head
Novartis



Surendera Tyagi
Senior Vice President Head
Innovation & Development
Center **Fresenius Kabi**



Yvonne Perrie
Chair Drug Delivery
University of Strathclyde

Commercial Partners

If you're interested in becoming an official partner for the DDF Summit, please contact

Alexandra Krcho

alexandra.krcho@markallengroup.com
+44 (0) 203 874 9205.



DATWYLER

Datwyler Pharma Packaging
International
www.datwyler.com



Glatt[®]

Glatt
www.glatt.com



ADARE
Pharmaceuticals™

Adare Pharmaceuticals
www.adarepharma.com



armorpharma
Technological Lactose Excipients

Armor Pharma
www.armor-pharma.com



DFE pharma

DFE Pharma
www.dfepharm.com



GRACE
Talent | Technology | Trust™

Grace
www.grace.com



Agilent Technologies

Agilent Technologies
www.agilent.com

Capsugel

Now a **Lonza** Company

Capsugel, now a Lonza
Company
www.capsugel.com



DOW

Dow Pharma & Medical
www.dowpharmasolutions.com



HARKE
Pharma

HARKE Pharma
www.harke.com



Albumedix

Albumedix
www.albumedix.com



CAPTISOL[®]

Captisol
www.captisol.com



FOSTER
DELIVERY SCIENCE

Foster Delivery Science
www.deliveryscience.com



Hovione

Hovione
www.hovione.com

Commercial Partners *continued*



Leon-nanodrugs
www.leon-nanodrugs.com

Merck KGaA
Darmstadt, Germany

Merck KGaA
www.merckgroup.com



Quotient Clinical
www.quotientclinical.com



ShinEtsu
www.se-pfmd.com



Losan Pharma
www.losan-pharma.de



Munit
www.munit.com



Renishaw
www.renishaw.com



SIO
www.admsio.com



LTS Lohmann
www.ltslohm.de



Patheon
www.patheon.com



REVOX Sterilization Solutions
www.revaxterilization.com



Unchained Labs
www.unchainedlabs.com



Meggle Excipients & Technology
www.meggle-pharma.com



Pfanstiehl
www.pfanstiehl.com



Roquette
www.roquette.com



W. L. Gore & Associates
www.gore.co.uk

Who attends the DDF Summit?

The 2017 summit was the biggest to date with 350 senior pharmaceutical development leaders joining us in Berlin for the 3 days. Here's how that 350 break down:

By company type:


Pharmaceuticals: 63.4%

Delivery / Formulation Services: 26%


University: 8.3%

Regulatory Agency: 2.3%

By job function:



By seniority:



"The DDF event is getting better with every year... It is really worth coming."


Monika Brink, Senior Manager,
Outsourcing R&D CMC,
Boehringer Ingelheim Vetmedica

Who attends the DDF Summit? *continued*

By country:

Top 10 countries:

1 Germany	28.4%
2 United Kingdom	11.9%
3 Denmark	8.8%
4 United States	7.7%
5 France	6.5%
6 Switzerland	6.1%
7 Belgium	5.4%
8 Netherlands	3.5%
9 Sweden	2.7%
10 Italy	1.9%




Other countries represented include:

Japan Portugal Ireland
 South Korea Jordan Spain
 Austria Finland Canada
 Turkey Croatia Norway
 Hungary Poland Czech Republic
 India Iran
 Brazil Cuba

By investment priorities:

Of the 65 delegates taking part in iSolve meetings...
 % looking to invest in:



*“Very good,
 smart people,
 very interesting
 talks”*

Laugier Maxime, VP,
 Pharma Development,
 Poxel Pharma

How to register

Delegate registration is open to companies with a drug development pipeline or proprietary drugs in the market and academic / non-profit / government institutions.

If you work for a **technology, service or solution provider** then you can only attend as a commercial partner. Please go to the next page for more information.

A delegate ticket includes:

- Access to all presentations on all 3 days
- Access to exhibition hall
- Potential for 2 pre-arranged 1-2-1 meetings with suppliers most likely to solve your challenges
- A light breakfast, full buffet lunch and refreshments on all 3 days
- 2 evening drinks receptions with canapes
- A discounted room rate at the venue hotel
- Access to all presentations made available by speakers after the summit
- Opportunity to submit a poster to the poster competition
- Access to the official summit app

Prices:

Register by 8th December: £1,195 + VAT

Full Price: £1,495 + VAT

Group Discounts:

2 Delegates: £100 off each

3 Delegates: £200 off each

To register, please

Visit: www.ddfevent.com/book-now

Email: maxconferences@markallengroup.com

Call: +44 (0) 207 738 5454

Become a Commercial Partner

As an official DDF Summit commercial partner, you can benefit from:

- **3 days of varied networking opportunities** - providing you with ample time to meet and get to know the 200+ pharma development leaders in attendance
- **Speaking positions within targeted, highly technical streams** - guaranteeing you a relevant and engaged audience
- **Exposure** in the pre- and post-summit marketing campaigns
- The chance for your team to get up to speed with the **latest innovations** and **advances** in drug delivery and formulation

There are a variety of options available to meet your business needs:

Business Development Package – a powerful injection of high quality leads into your pipeline

Thought Leadership Package – Intrigue, challenge and inspire with your innovative ideas and solutions

Bespoke Package – Tailored to suit your targets, goals and vision

Contact Alexandra for more information on the remaining opportunities.

Alexandra Krcho, Account Director
+44 (0) 203 874 9205 | alexandra.krcho@markallengroup.com

Venue

Maritim proArte Hotel Berlin

Friedrichstrasse 151
10117 Berlin
Germany

+49 30 20 335

[Website](#)

Accommodation

This is not included in your delegate ticket.
You will need to arrange your own accommodation.
However, we have arranged a discounted rate for all attendees at the Maritim proArte – more information is available [here](#)

Contact us

If you'd like to speak to us about anything at all then please use the details below:

General Enquiries:

+44 (0)20 7738 5454
maxconferences@markallengroup.com

Conference Content & Speaking:

Ahmed Osman, Programme Director
+ 44 (0)20 3874 9202
ahmed.osman@markallengroup.com

Sponsorship Enquiries:

Alexandra Krcho, Account Director
+ 44 (0) 203 874 9205
alexandra.krcho@markallengroup.com

Delegate Enquiries:

Adrian Forde, Delegate Sales Director
+ 44 (0)20 3874 9209
adrian.forde@markallengroup.com

Marketing & Media Enquiries:

Josh Lowth, Marketing Director
+44 (0)203 874 9210
josh.lowth@markallengroup.com

